Loading...

Cyxone

DB:4CX
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4CX
DB
SEK119M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cyxone AB (publ), a clinical biotech company, develops cyclotide drugs for autoimmune and other diseases. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • Cyxone has significant price volatility in the past 3 months.
4CX Share Price and Events
7 Day Returns
5.6%
DB:4CX
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:4CX
-10.2%
DE Biotechs
-6%
DE Market
4CX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cyxone (4CX) 5.6% -1% -12.2% - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 4CX.
  • No trading data on 4CX.
Price Volatility
4CX
Industry
5yr Volatility vs Market

Value

 Is Cyxone undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cyxone. This is due to cash flow or dividend data being unavailable. The share price is €0.301.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cyxone's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cyxone's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4CX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-0.56
OM:CYXO Share Price ** OM (2019-04-18) in SEK SEK3.18
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cyxone.

DB:4CX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:CYXO Share Price ÷ EPS (both in SEK)

= 3.18 ÷ -0.56

-5.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyxone is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cyxone is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cyxone's expected growth come at a high price?
Raw Data
DB:4CX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cyxone, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cyxone's assets?
Raw Data
DB:4CX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK1.88
OM:CYXO Share Price * OM (2019-04-18) in SEK SEK3.18
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:4CX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:CYXO Share Price ÷ Book Value per Share (both in SEK)

= 3.18 ÷ 1.88

1.69x

* Primary Listing of Cyxone.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyxone is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cyxone's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cyxone has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cyxone expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Cyxone expected to grow at an attractive rate?
  • Unable to compare Cyxone's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cyxone's earnings growth to the Germany market average as no estimate data is available.
  • Cyxone's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4CX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4CX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 40%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4CX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4CX Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -28 1
2020-12-31 89 67 1
2019-12-31 0 -17 1
DB:4CX Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -14 -15
2018-09-30 -13 -14
2018-06-30 -10 -11
2018-03-31 -4 -10
2017-12-31 -5 -9
2017-09-30 0 -6 -7
2017-06-30 -8 -7
2017-03-31 -5 -5
2016-12-31 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cyxone is high growth as no earnings estimate data is available.
  • Cyxone's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4CX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cyxone Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4CX Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
DB:4CX Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -0.56
2018-09-30 -0.75
2018-06-30 -0.65
2018-03-31 -0.62
2017-12-31 -0.57
2017-09-30 -0.49
2017-06-30 -0.50
2017-03-31 -0.35
2016-12-31 -0.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cyxone will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cyxone's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cyxone has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cyxone performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cyxone's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cyxone does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Cyxone's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cyxone's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cyxone's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cyxone Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4CX Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.00 -15.43 2.23
2018-09-30 -14.12 14.02
2018-06-30 -11.25 11.25
2018-03-31 -10.08 10.05
2017-12-31 -8.82 2.29
2017-09-30 -0.02 -6.73 2.07
2017-06-30 -6.61 3.91
2017-03-31 -5.18 2.46
2016-12-31 -4.00 1.32
2015-12-31 0.04 -0.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cyxone has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cyxone has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cyxone improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cyxone's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cyxone has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cyxone's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cyxone's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cyxone is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cyxone has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cyxone's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cyxone has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cyxone Company Filings, last reported 3 months ago.

DB:4CX Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 70.55 0.00 38.72
2018-09-30 38.93 0.00 10.48
2018-06-30 30.63 0.00 17.82
2018-03-31 34.39 0.00 27.23
2017-12-31 37.13 0.00 33.36
2017-09-30 28.65 0.00 25.66
2017-06-30 30.17 0.00 28.11
2017-03-31 32.76 0.00 31.28
2016-12-31 22.83 0.00 21.60
2015-12-31 0.34 0.00 0.01
  • Cyxone has no debt.
  • Cyxone has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cyxone has less than a year of cash runway based on current free cash flow.
  • Cyxone has less than a year of cash runway if free cash flow continues to grow at historical rates of 88.9% each year.
X
Financial health checks
We assess Cyxone's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cyxone has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cyxone's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cyxone dividends.
If you bought €2,000 of Cyxone shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cyxone's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cyxone's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4CX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4CX Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cyxone has not reported any payouts.
  • Unable to verify if Cyxone's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cyxone's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cyxone has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cyxone's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cyxone afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cyxone has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cyxone's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kjell Stenberg
AGE 66
CEO Bio

Dr. Kjell G. Stenberg, Ph.D., serves as the Chief Executive Officer of Cyxone AB (publ). Dr. Stenberg serves as the Chief Marketing Officer of Aptahem AB (publ) and serves as its Chairman. Dr. Stenberg serves as the Chief Executive Officer of Accequa AB and Celus Parmaceuticals Ltd, USA. He is the owner of Biomedical Development Europe. He served as the Chief Operating Officer of Medwell Capital Corp. from November 17, 2005 to October 5, 2010. He served as Partner of Medwell Capital Corp. Dr. Stenberg has 25 years experience from management positions in R&D. He was the founder of Combio A/S in 2001 and served as its Chief Executive Officer. He served as Chief Scientific Officer positions in CePeP AB and Orexo AB. He served as Chief Operating Officer of BioMS Medical Corp. He served as Senior Researcher, Director and Manager of Astra/AstraZeneca from 1975 to 2000, where he was involved in bringing various drugs to market either as Director of Research or Director of Development. From 1975 to 2000, Dr. Stenberg held senior research and management positions at Astra and AstraZeneca, where his responsibilities included directing research in multiple sclerosis, management of international development teams and being the Director of External Alliances for the development of products related to the Central Nervous System (which included MS). Dr. Stenberg has also been involved with three biotech companies at the level of Founder, Chief Executive Officer and Chief Scientific Officer. He served as a Director of PCI Biotech AS since 2013. He serves as the Chairman of The Board at Galecto Biotech AB. He served as a Director of Cyxone AB (publ). He serves as a Director of Novation Pharmaceuticals, Inc., Galecto AB and Aptahem AB (publ). He served as a Director of PCI Biotech Holding ASA since May 6, 2013 until 2015. He served as a Director of Medwell Capital Corp. from 2002 to October 5, 2010. He has published extensively in the field of oncology and cell toxicology. He served as Director of Orexo AB. Dr. Stenberg holds a Ph.D. in Medical Science from the Karolinska Institute, Sweden.

CEO Compensation
  • Insufficient data for Kjell to compare compensation growth.
  • Insufficient data for Kjell to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Kjell Stenberg

TITLE
Chief Executive Officer
AGE
66

Ola Skanung

TITLE
Chief Financial Officer

Mikael Lindstam

TITLE
COO & Director
AGE
52
Board of Directors

Bert Junno

TITLE
Chairman of the Board
AGE
52

Mikael Lindstam

TITLE
COO & Director
AGE
52

Christian Gruber

TITLE
Chairman of the Scientific Advisory Board

Saad Gilani

TITLE
Director
AGE
47

Carsten Gründemann

TITLE
Member of the Scientific Advisory Board

Theresa Comiskey Olsen

TITLE
Director
AGE
55
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cyxone's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cyxone has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cyxone AB (publ), a clinical biotech company, develops cyclotide drugs for autoimmune and other diseases. Its lead candidate is Rabeximod, which is in Phase II clinical trial for the treatment of patients with rheumatoid arthritis. The company also develops T20K that is in pre-clinical trial for the treatment of pro-inflammatory cytokines, such as IL2 and reduces clinical symptoms in an animal model for multiple sclerosis after oral administration. The company was founded in 2015 and is based in Malmo, Sweden.

Details
Name: Cyxone AB (publ)
4CX
Exchange: DB
Founded: 2015
SEK11,375,528
37,457,517
Website: http://www.cyxone.com
Address: Cyxone AB (publ)
Adelgatan 21,
Malmo,
Skåne County, 221 22,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM CYXO Share Capital OMX Nordic Exchange Stockholm SE SEK 07. Jun 2016
DB 4CX Share Capital Deutsche Boerse AG DE EUR 07. Jun 2016
Number of employees
Current staff
Staff numbers
4
Cyxone employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:12
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/04/02
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.